AtriCure (NASDAQ:ATRC) Updates FY 2024 Earnings Guidance

AtriCure (NASDAQ:ATRC) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.800–0.740 for the period, compared to the consensus earnings per share estimate of -0.790. The company issued revenue guidance of $459.0 million-$462.0 million, compared to the consensus revenue estimate of $458.1 million.

AtriCure Trading Up 0.9 %

ATRC traded up $0.29 during midday trading on Friday, reaching $33.47. 482,210 shares of the company’s stock were exchanged, compared to its average volume of 730,956. The company has a quick ratio of 2.93, a current ratio of 4.13 and a debt-to-equity ratio of 0.16. The business has a 50-day simple moving average of $27.86 and a two-hundred day simple moving average of $24.43. AtriCure has a one year low of $18.94 and a one year high of $43.00.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. The business had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative return on equity of 8.14% and a negative net margin of 8.70%. AtriCure’s revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS. Research analysts predict that AtriCure will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

ATRC has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price objective on shares of AtriCure from $49.00 to $53.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group raised their price target on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler cut their price objective on AtriCure from $65.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Oppenheimer raised their target price on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, BTIG Research cut their price target on AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.11.

Insider Activity

In related news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the sale, the director now directly owns 8,970 shares in the company, valued at $215,907.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is currently owned by insiders.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.